Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,000
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,963.50 | 29.20 | 0.33% |
CAC 40 | 7,800.88 | 33.70 | -0.43% |
DAX 40 | 23,970.36 | 247.14 | -1.02% |
Dow JONES (US) | 44,930.98 | 29.06 | 0.06% |
FTSE 100 | 9,081.44 | 38.87 | -0.43% |
HKSE | 25,562.13 | 173.78 | 0.68% |
NASDAQ | 21,167.13 | 58.81 | 0.28% |
Nikkei 225 | 40,998.27 | 457.96 | -1.10% |
NZX 50 Index | 12,910.74 | 57.28 | 0.45% |
S&P 500 | 6,393.18 | 4.54 | 0.07% |
S&P/ASX 200 | 8,697.70 | 30.80 | 0.36% |
SSE Composite Index | 3,597.94 | 4.28 | 0.12% |